Clinical Trials Using Brentuximab Vedotin

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Brentuximab Vedotin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 34
1 2 Next >

  • Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults with Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma

    This randomized phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB or stage IIIB-IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating Hodgkin lymphoma.
    Location: 174 locations

  • Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma

    This pilot phase I / II trial studies the side effects and the best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.
    Location: 18 locations

  • Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells called cluster of differentiation (CD)30 and may kill the cells. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.
    Location: 15 locations

  • Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Newly Diagnosed, Early Stage, Unfavorable-Risk Hodgkin Lymphoma

    This pilot clinical trial studies how well brentuximab vedotin works when given with combination chemotherapy and radiation therapy in treating patients with newly diagnosed, early stage, unfavorable-risk Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, may find cancer cells and help kill them by carrying cancer-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing them, by stopping them from dividing, or by stopping them from spreading. Involved-site radiation therapy uses high energy x rays to kill cancer cells. Giving brentuximab vedotin with combination chemotherapy and involved-site radiation therapy may kill more cancer cells and may have fewer side effects than other types of treatment.
    Location: 9 locations

  • An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

    The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).
    Location: 9 locations

  • Nivolumab and Brentuximab Vedotin in Treating Older Patients with Untreated Hodgkin Lymphoma

    This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older patients with untreated Hodgkin lymphoma. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. Biological therapies, such as brentuximab vedotin, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Nivolumab and brentuximab vedotin may work better in treating older patients with untreated Hodgkin lymphoma.
    Location: 8 locations

  • Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204 / KEYNOTE-204)

    The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma. Participants will be randomized to receive either pembrolizumab or brentuximab vedotin (BV) for up to 35 three-week cycles of treatment. The primary hypotheses of this study are that treatment with pembrolizumab prolongs Progression Free Survival (PFS) and Overall Survival (OS) in participants with relapsed or refractory Classical Hodgkin Lymphoma compared to treatment with BV.
    Location: 6 locations

  • Brentuximab Vedotin, Doxorubicin Hydrochloride, and Dacarbazine in Treating Patients with Previously Untreated Stage I-IIB Non-bulky Classical Hodgkin Lymphoma

    This phase II trial studies how well brentuximab vedotin, doxorubicin hydrochloride, and dacarbazine work in treating patients with stage I-IIB non-bulky Hodgkin lymphoma. Brentuximab vedotin may interfere with the ability of cancer cells to grow and spread by binding to a protein on the surface of cancer cells and then releasing a cancer-killing substance to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with doxorubicin hydrochloride and dacarbazine may kill more cancer cells.
    Location: 5 locations

  • Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma

    This pilot phase II trial studies the side effects and how well brentuximab vedotin, combination chemotherapy, and radiation therapy work in treating younger patients with stage IIB-IVB Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, find and attach to the surface of most lymphoma cells and may cause the cells to die. Drugs used in chemotherapy, such as etoposide, prednisone, doxorubicin hydrochloride, cyclophosphamide, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill cancer cells and shrink cancer. Giving brentuximab vedotin with combination chemotherapy and radiation therapy may kill more cancer cells and may also reduce the late side effects caused by chemotherapy or radiation therapy.
    Location: 5 locations

  • A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed / Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

    The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant
    Location: 4 locations

  • A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

    The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
    Location: 5 locations

  • Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas

    This phase I / II trial studies the side effects and best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with untreated large B-cell lymphoma, diffuse large B-cell lymphoma or gray zone lymphomas. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells.
    Location: 3 locations

  • Brentuximab Vedotin and Rituximab in Treating Patients with Lymphomas Associated with Immunosuppression

    This phase I / II trial studies the side effects and best dose of brentuximab vedotin and to see how well it works when given together with rituximab in treating patients with lymphomas associated with suppression of the body's immune system and its ability to fight infections and other diseases. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving brentuximab vedotin with rituximab may kill more cancer cells.
    Location: 3 locations

  • Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Germ Cell Tumors

    This phase II trial studies how well brentuximab vedotin works in treating patients with germ cell tumors that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread.
    Location: 2 locations

  • Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

    Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated). Following recovery, patients will receive a medication called Brentuximab Vendotin which is targeted against CD30+ cells. The study hypothesis is that this treatment will be safe and well tolerated in children and young adults.
    Location: 3 locations

  • Brentuximab Vedotin, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

    This phase I trial studies the side effects and the best dose of brentuximab vedotin when given together with mitoxantrone hydrochloride, etoposide, and cytarabine in treating patients with acute myeloid leukemia that has returned or does not respond to treatment. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with mitoxantrone hydrochloride, etoposide, and cytarabine may kill more cancer cells.
    Location: 2 locations

  • A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

    This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin as a single-agent (Part A) and in combination with dacarbazine (Part B), bendamustine (Part C), or nivolumab (Part D) in front-line therapy of HL in adults age 60 and above.
    Location: 2 locations

  • Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma

    This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Monoclonal antibodies, such as brentuximab vedotin may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.
    Location: 3 locations

  • Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma

    This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as nivolumab and brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread.
    Location: 6 locations

  • Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of brentuximab vedotin and cyclosporine when given together with verapamil hydrochloride in treating patients with Hodgkin lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Immunosuppressive therapies, such as cyclosporine, may improve bone marrow function and increase blood cell counts. Verapamil hydrochloride may increase the effectiveness of brentuximab vedotin by overcoming drug resistance of the cancer cells. Giving brentuximab vedotin, cyclosporine, and verapamil hydrochloride may work better in treating patients with Hodgkin lymphoma.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

    This phase II trial studies how well brentuximab vedotin works in treating patients with CD30+ malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Brentuximab Vedotin and Bevacizumab in Treating Patients with Recurrent and Refractory CD-30 Positive Germ Cell Tumors

    This phase II trial studies how well brentuximab vedotin and bevacizumab work in treating patients with CD-30 positive germ cell tumors that has come back and does not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin and bevacizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota

  • Total Skin Electron Beam Radiation Therapy and Brentuximab Vedotin in Treating Patients with Stage IB-IVA Mycosis Fungoides, Sezary Syndrome, or Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

    This phase Ib trial studies the side effects of total skin electron beam ration therapy when given together with brentuximab vedotin and the see how well they work in treating patients with stage IB-IVA mycosis fungoides, Sezary syndrome or primary cutaneous T-cell non-Hodgkin lymphoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread. Giving total skin electron beam ration therapy and brentuximab vedotin may work better in treating patients with mycosis fungoides, Sezary syndrome or primary cutaneous T-cell non-Hodgkin lymphoma.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Ibrutinib and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma

    This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.
    Location: 4 locations

  • Romidepsin and Brentuximab Vedotin in Treating Patients with Cutaneous T-cell Lymphoma

    This phase I trial studies the best dose and side effects of romidepsin when given together with brentixumab vedotin in treating patients with cutaneous T-cell lymphoma. Romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Giving romidepsin and brentuximab vedotin together may work better in treating patients with cutaneous T-cell lymphoma.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania


1 2 Next >